Sixth, using publicly available expression microarray data (Oncomine), we demonstrate that three of the genes that contained probes optimized for HRM analysis (see paragraph below) show increased expression in many different cancer types such as leukemia, ovarian and pancreatic cancer (GPM6B and FCRL1), renal and colorectal cancer (GPM6B and MAGEA12), HCC and breast cancer (MAGEA12 and FCRL1), testicular cancer and melanoma (significant overexpression of GPM6B in both cancers and MAGEA12 in melanoma) (Figure 1D–F). This evidence concerns the gene GPM6B and familial pancreatic carcinoma.